A clinical trial to study the effect of Triflusal in Aspirin resitant patients
Phase 4
Completed
- Conditions
- Health Condition 1: null- Aspirin Resistant patients with Type 2 Diabetes mellitus or documented CHD
- Registration Number
- CTRI/2011/04/001679
- Lead Sponsor
- Glenmark Pharmaceuticals Lts
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 40
Inclusion Criteria
?Patients with Type 2 Diabetes mellitus or documented Coronary Heart Disease on a stable dose of Aspirin# and detected to be having Aspirin Resistance.
Stable dose of Aspirin - Patient on Aspirin on a particular dosage for more than 7 days.
Aspirin Resistance - Determined by increased Thromboxane B2 (TxB2) levels in urine using AspirinWorks® Test Kit.
?Patients willing to provide informed consent and comply to the protocol.
Exclusion Criteria
?Concomitant therapy with NSAIDs
?History of active peptic ulcer
Study & Design
- Study Type
- PMS
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method